Ligand Pharmaceuticals Inc
LGNZZ- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000886163
In the last 90 days, Ligand Pharmaceuticals Inc insiders filed 0 open-market purchases and 6 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Holders of 5% or more of LGNZZ
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Ligand Pharmaceuticals Inc, largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Ligand Pharmaceuticals Inc on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
Schedule 13D and 13G filings on Ligand Pharmaceuticals Inc, newest first.
No Schedule 13D or 13G filings on Ligand Pharmaceuticals Inc are on file.
Form 144: proposed insider sales
3 notices from officers, directors and other affiliates planning to sell Ligand Pharmaceuticals Inc shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| May 16, 20231:14 PM ET | John W. KozarichBoard of Directors | 4.44K | $343.1K | May 16, 2023 | UBS Financial Services Inc | SEC |
| May 10, 20237:07 PM ET | Sabba Stephen LOfficer | 6.41K | $494.2K | May 10, 2023 | ETRADE FINANCIAL CORPORATION | SEC |
| May 8, 20235:12 PM ET | Kozarich John WOfficer | 6.41K | $487.0K | May 8, 2023 | ETRADE FINANCIAL CORPORATION | SEC |